- IBDEI0IY ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,8528,1,3,0)
- ;;=3^Carcinoma in Situ of Endocervix
- ;;^UTILITY(U,$J,358.3,8528,1,4,0)
- ;;=4^D06.0
- ;;^UTILITY(U,$J,358.3,8528,2)
- ;;=^5001938
- ;;^UTILITY(U,$J,358.3,8529,0)
- ;;=D06.1^^39^401^48
- ;;^UTILITY(U,$J,358.3,8529,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8529,1,3,0)
- ;;=3^Carcinoma in Situ of Exocervix
- ;;^UTILITY(U,$J,358.3,8529,1,4,0)
- ;;=4^D06.1
- ;;^UTILITY(U,$J,358.3,8529,2)
- ;;=^5001939
- ;;^UTILITY(U,$J,358.3,8530,0)
- ;;=D06.7^^39^401^46
- ;;^UTILITY(U,$J,358.3,8530,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8530,1,3,0)
- ;;=3^Carcinoma in Situ of Cervix,Other Parts
- ;;^UTILITY(U,$J,358.3,8530,1,4,0)
- ;;=4^D06.7
- ;;^UTILITY(U,$J,358.3,8530,2)
- ;;=^5001940
- ;;^UTILITY(U,$J,358.3,8531,0)
- ;;=D04.9^^39^401^49
- ;;^UTILITY(U,$J,358.3,8531,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8531,1,3,0)
- ;;=3^Carcinoma in Situ of Skin
- ;;^UTILITY(U,$J,358.3,8531,1,4,0)
- ;;=4^D04.9
- ;;^UTILITY(U,$J,358.3,8531,2)
- ;;=^5001925
- ;;^UTILITY(U,$J,358.3,8532,0)
- ;;=C91.11^^39^401^52
- ;;^UTILITY(U,$J,358.3,8532,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8532,1,3,0)
- ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
- ;;^UTILITY(U,$J,358.3,8532,1,4,0)
- ;;=4^C91.11
- ;;^UTILITY(U,$J,358.3,8532,2)
- ;;=^5001766
- ;;^UTILITY(U,$J,358.3,8533,0)
- ;;=C91.10^^39^401^53
- ;;^UTILITY(U,$J,358.3,8533,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8533,1,3,0)
- ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
- ;;^UTILITY(U,$J,358.3,8533,1,4,0)
- ;;=4^C91.10
- ;;^UTILITY(U,$J,358.3,8533,2)
- ;;=^5001765
- ;;^UTILITY(U,$J,358.3,8534,0)
- ;;=C92.11^^39^401^54
- ;;^UTILITY(U,$J,358.3,8534,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8534,1,3,0)
- ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
- ;;^UTILITY(U,$J,358.3,8534,1,4,0)
- ;;=4^C92.11
- ;;^UTILITY(U,$J,358.3,8534,2)
- ;;=^5001793
- ;;^UTILITY(U,$J,358.3,8535,0)
- ;;=C92.10^^39^401^55
- ;;^UTILITY(U,$J,358.3,8535,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8535,1,3,0)
- ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
- ;;^UTILITY(U,$J,358.3,8535,1,4,0)
- ;;=4^C92.10
- ;;^UTILITY(U,$J,358.3,8535,2)
- ;;=^5001792
- ;;^UTILITY(U,$J,358.3,8536,0)
- ;;=D47.1^^39^401^56
- ;;^UTILITY(U,$J,358.3,8536,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8536,1,3,0)
- ;;=3^Chronic Myeloproliferative Disease
- ;;^UTILITY(U,$J,358.3,8536,1,4,0)
- ;;=4^D47.1
- ;;^UTILITY(U,$J,358.3,8536,2)
- ;;=^5002256
- ;;^UTILITY(U,$J,358.3,8537,0)
- ;;=C82.69^^39^401^57
- ;;^UTILITY(U,$J,358.3,8537,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8537,1,3,0)
- ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
- ;;^UTILITY(U,$J,358.3,8537,1,4,0)
- ;;=4^C82.69
- ;;^UTILITY(U,$J,358.3,8537,2)
- ;;=^5001530
- ;;^UTILITY(U,$J,358.3,8538,0)
- ;;=C82.60^^39^401^58
- ;;^UTILITY(U,$J,358.3,8538,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8538,1,3,0)
- ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
- ;;^UTILITY(U,$J,358.3,8538,1,4,0)
- ;;=4^C82.60
- ;;^UTILITY(U,$J,358.3,8538,2)
- ;;=^5001521
- ;;^UTILITY(U,$J,358.3,8539,0)
- ;;=D56.2^^39^401^59
- ;;^UTILITY(U,$J,358.3,8539,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8539,1,3,0)
- ;;=3^Delta-Beta Thalassemia
- ;;^UTILITY(U,$J,358.3,8539,1,4,0)
- ;;=4^D56.2
- ;;^UTILITY(U,$J,358.3,8539,2)
- ;;=^340496
- ;;^UTILITY(U,$J,358.3,8540,0)
- ;;=D75.9^^39^401^60
- ;;^UTILITY(U,$J,358.3,8540,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,8540,1,3,0)
- ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0IY 3825 printed Feb 18, 2025@23:15:58 Page 2
- IBDEI0IY ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,8528,1,3,0)
- +2 ;;=3^Carcinoma in Situ of Endocervix
- +3 ;;^UTILITY(U,$J,358.3,8528,1,4,0)
- +4 ;;=4^D06.0
- +5 ;;^UTILITY(U,$J,358.3,8528,2)
- +6 ;;=^5001938
- +7 ;;^UTILITY(U,$J,358.3,8529,0)
- +8 ;;=D06.1^^39^401^48
- +9 ;;^UTILITY(U,$J,358.3,8529,1,0)
- +10 ;;=^358.31IA^4^2
- +11 ;;^UTILITY(U,$J,358.3,8529,1,3,0)
- +12 ;;=3^Carcinoma in Situ of Exocervix
- +13 ;;^UTILITY(U,$J,358.3,8529,1,4,0)
- +14 ;;=4^D06.1
- +15 ;;^UTILITY(U,$J,358.3,8529,2)
- +16 ;;=^5001939
- +17 ;;^UTILITY(U,$J,358.3,8530,0)
- +18 ;;=D06.7^^39^401^46
- +19 ;;^UTILITY(U,$J,358.3,8530,1,0)
- +20 ;;=^358.31IA^4^2
- +21 ;;^UTILITY(U,$J,358.3,8530,1,3,0)
- +22 ;;=3^Carcinoma in Situ of Cervix,Other Parts
- +23 ;;^UTILITY(U,$J,358.3,8530,1,4,0)
- +24 ;;=4^D06.7
- +25 ;;^UTILITY(U,$J,358.3,8530,2)
- +26 ;;=^5001940
- +27 ;;^UTILITY(U,$J,358.3,8531,0)
- +28 ;;=D04.9^^39^401^49
- +29 ;;^UTILITY(U,$J,358.3,8531,1,0)
- +30 ;;=^358.31IA^4^2
- +31 ;;^UTILITY(U,$J,358.3,8531,1,3,0)
- +32 ;;=3^Carcinoma in Situ of Skin
- +33 ;;^UTILITY(U,$J,358.3,8531,1,4,0)
- +34 ;;=4^D04.9
- +35 ;;^UTILITY(U,$J,358.3,8531,2)
- +36 ;;=^5001925
- +37 ;;^UTILITY(U,$J,358.3,8532,0)
- +38 ;;=C91.11^^39^401^52
- +39 ;;^UTILITY(U,$J,358.3,8532,1,0)
- +40 ;;=^358.31IA^4^2
- +41 ;;^UTILITY(U,$J,358.3,8532,1,3,0)
- +42 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
- +43 ;;^UTILITY(U,$J,358.3,8532,1,4,0)
- +44 ;;=4^C91.11
- +45 ;;^UTILITY(U,$J,358.3,8532,2)
- +46 ;;=^5001766
- +47 ;;^UTILITY(U,$J,358.3,8533,0)
- +48 ;;=C91.10^^39^401^53
- +49 ;;^UTILITY(U,$J,358.3,8533,1,0)
- +50 ;;=^358.31IA^4^2
- +51 ;;^UTILITY(U,$J,358.3,8533,1,3,0)
- +52 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
- +53 ;;^UTILITY(U,$J,358.3,8533,1,4,0)
- +54 ;;=4^C91.10
- +55 ;;^UTILITY(U,$J,358.3,8533,2)
- +56 ;;=^5001765
- +57 ;;^UTILITY(U,$J,358.3,8534,0)
- +58 ;;=C92.11^^39^401^54
- +59 ;;^UTILITY(U,$J,358.3,8534,1,0)
- +60 ;;=^358.31IA^4^2
- +61 ;;^UTILITY(U,$J,358.3,8534,1,3,0)
- +62 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
- +63 ;;^UTILITY(U,$J,358.3,8534,1,4,0)
- +64 ;;=4^C92.11
- +65 ;;^UTILITY(U,$J,358.3,8534,2)
- +66 ;;=^5001793
- +67 ;;^UTILITY(U,$J,358.3,8535,0)
- +68 ;;=C92.10^^39^401^55
- +69 ;;^UTILITY(U,$J,358.3,8535,1,0)
- +70 ;;=^358.31IA^4^2
- +71 ;;^UTILITY(U,$J,358.3,8535,1,3,0)
- +72 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
- +73 ;;^UTILITY(U,$J,358.3,8535,1,4,0)
- +74 ;;=4^C92.10
- +75 ;;^UTILITY(U,$J,358.3,8535,2)
- +76 ;;=^5001792
- +77 ;;^UTILITY(U,$J,358.3,8536,0)
- +78 ;;=D47.1^^39^401^56
- +79 ;;^UTILITY(U,$J,358.3,8536,1,0)
- +80 ;;=^358.31IA^4^2
- +81 ;;^UTILITY(U,$J,358.3,8536,1,3,0)
- +82 ;;=3^Chronic Myeloproliferative Disease
- +83 ;;^UTILITY(U,$J,358.3,8536,1,4,0)
- +84 ;;=4^D47.1
- +85 ;;^UTILITY(U,$J,358.3,8536,2)
- +86 ;;=^5002256
- +87 ;;^UTILITY(U,$J,358.3,8537,0)
- +88 ;;=C82.69^^39^401^57
- +89 ;;^UTILITY(U,$J,358.3,8537,1,0)
- +90 ;;=^358.31IA^4^2
- +91 ;;^UTILITY(U,$J,358.3,8537,1,3,0)
- +92 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
- +93 ;;^UTILITY(U,$J,358.3,8537,1,4,0)
- +94 ;;=4^C82.69
- +95 ;;^UTILITY(U,$J,358.3,8537,2)
- +96 ;;=^5001530
- +97 ;;^UTILITY(U,$J,358.3,8538,0)
- +98 ;;=C82.60^^39^401^58
- +99 ;;^UTILITY(U,$J,358.3,8538,1,0)
- +100 ;;=^358.31IA^4^2
- +101 ;;^UTILITY(U,$J,358.3,8538,1,3,0)
- +102 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
- +103 ;;^UTILITY(U,$J,358.3,8538,1,4,0)
- +104 ;;=4^C82.60
- +105 ;;^UTILITY(U,$J,358.3,8538,2)
- +106 ;;=^5001521
- +107 ;;^UTILITY(U,$J,358.3,8539,0)
- +108 ;;=D56.2^^39^401^59
- +109 ;;^UTILITY(U,$J,358.3,8539,1,0)
- +110 ;;=^358.31IA^4^2
- +111 ;;^UTILITY(U,$J,358.3,8539,1,3,0)
- +112 ;;=3^Delta-Beta Thalassemia
- +113 ;;^UTILITY(U,$J,358.3,8539,1,4,0)
- +114 ;;=4^D56.2
- +115 ;;^UTILITY(U,$J,358.3,8539,2)
- +116 ;;=^340496
- +117 ;;^UTILITY(U,$J,358.3,8540,0)
- +118 ;;=D75.9^^39^401^60
- +119 ;;^UTILITY(U,$J,358.3,8540,1,0)
- +120 ;;=^358.31IA^4^2
- +121 ;;^UTILITY(U,$J,358.3,8540,1,3,0)
- +122 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
